CRY 12.5
CryoLife, Inc. develops and commercializes biomaterials and implantable medical devices in the United States and internationally. The company's product includes BioGlue, a polymer based on bovine blood protein and an agent for cross-linking proteins designed for cardiac, vascular, pulmonary, and general surgical applications, as well as used as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. It markets BioGlue to physicians and distributes it through its technical representatives, as well as provides soft tissue repairs. The company also distributes CardioWrap, a bioresorbable sheet used to replace the pericardium in cardiac reconstruction and other cardiac surgeries; CryoLife-O'Brien Stentless Porcine Aortic Bioprosthesis, a porcine heart valve that contains minimal amounts of synthetic material compared to other glutaraldehyde-fixed porcine valves, which reduces endocarditis, debilitating, and potentially fatal infection; and ProPatch that is used to reinforce weakened soft tissues and provides a resorbable scaffold, which is replaced by the patient's own soft tissue. In addition, CryoLife, Inc. preserves and distributes human tissues for cardiac and vascular transplant applications. It provides natural blood flow properties for its preserved human heart valves, prevent excessive blood clotting, and reduce risk of catastrophic failure, thromboembolism, and calcification. The company was founded in 1984 and is based in Kennesaw, Georgia.
 |
